A Phase 3 Study of RMC-6236 Versus Docetaxel in People With Advanced Non-Small Cell Lung Cancer

Full Title

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

Purpose

Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene.

RMC-6236 targets the proteins made by a RAS gene mutation and prevent the RAS protein from sending growth signals. By blocking these signals, RMC-6236 may help slow or stop the growth of your cancer cells.

If you take part in this study, you will be randomly assigned to get either RMC-6236 or docetaxel. RMC-6236 is taken orally (by mouth) and docetaxel is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.